Editorial: Emerging Therapies for Malignant Mesothelioma.

Keywords: malignant mesothelioma; tumor biology; preclinical models; immune environment; angiogenesis inhibitors; chemotherapy; immunotherapy; microRNA EN malignant mesothelioma tumor biology preclinical models immune environment angiogenesis inhibitors chemotherapy immunotherapy microRNA 1 2 2 06/16/20 20200612 NES 200612 Malignant mesothelioma, resistant to most currently available therapies, is associated with the lowest survival rates of any major cancer type. Although some activity of experimental approaches such as intrapleural pro-inflammatory cytokines was noted in the 1990s ([1]-[4]), chemotherapy-based therapies, surgery and radiotherapy dominated clinical research into mesothelioma treatment through the 1990s and 2000s. Malignant mesothelioma, tumor biology, preclinical models, immune environment, angiogenesis inhibitors, chemotherapy, immunotherapy, microRNA. [Extracted from the article]